NovoCare Pharmacy (Wegovy self-pay)

What you actually pay

Novo Nordisk sells Wegovy directly for cash, and the headline figures are genuinely low — but almost all of them are introductory, and the site is specific about when they end.

The $199 pen price applies to the first two monthly fills only. Novo's own footnote reads: "Offer is for 2 monthly fills through December 31, 2026, then $349 per month" — and $399 per month for Wegovy HD. The $149 price on 4 mg oral tablets was "only available until August 31, 2026, then $199 per month". So a buyer comparing $199 against a competitor's ongoing rate is comparing two different things: the third fill costs $349, and nothing on the pricing page frames it as temporary at the point where the number appears.

Beyond that, this is straightforward. There is no membership, no subscription and no contract — you pay per fill. Shipping and delivery are free, a 90-day supply is available if your prescriber writes it, and you can switch to local pickup by calling. FSA and HSA cards are accepted, and no copay card needs activating.

What NovoCare does not do

It does not prescribe. Novo states plainly: "You will need to speak to a licensed health care provider." Novo will refer you to independent telehealth companies, and disclaims them in the same breath — "Novo Nordisk does not make any representations or guarantees about the qualifications, competence, or skills of any health care provider", and it takes no payment for the referrals. Their consultation fees are separate and are not disclosed on Novo's referral page.

There is no coaching, no dietitian, no labs and no clinical messaging. Whether needles or injection supplies are included is not addressed anywhere on the pages we reviewed.

The self-pay attestation

To use these prices you must certify that you "will not seek reimbursement or otherwise submit a claim to any insurer (primary, secondary, commercial, employer, government nor supplemental)". Novo spells out the consequence: your prescription "will not count toward any deductibles, and cannot be applied to any insurance maximum out-of-pocket limits."

Unusually, government-insured patients are not excluded from self-pay — Novo says they "may use this program if they self pay and process outside of their insurance". The separate commercial-insurance savings offer does exclude them.

Notably, unlike Lilly, Novo attaches no refill deadline to its self-pay price. There is no 45-day clock here.

Where the site contradicts itself

Novo's FAQ says the programme "may be an option for you if you don't have insurance or if your insurance benefits don't cover your medicine". Its own pharmacy terms say the opposite: patients "must either be uninsured or have insurance (either commercial or government-funded), but decide to self-pay". A reader whose plan does cover Wegovy would be told by one paragraph that they do not qualify, and by two others that they do.

Practical friction

"NovoCare Pharmacy" is a brand over third parties — AssistRx handles support, and CoAssist Pharmacy and CenterWell Pharmacy do the dispensing. Novo's own FAQ anticipates the confusion with an entry titled "Why did I get a text message from CenterWell Pharmacy or CoAssist Pharmacy?"

Onboarding runs entirely by text, and depends on your prescriber transcribing your mobile number correctly. Support is split across at least four phone numbers by issue type. No refund or cancellation policy is published at all.

Multi-month fills save nothing

NovoCare's tables price one, two and three months of every product, and each longer column is simply the monthly price multiplied. The 1.5 mg tablets read "$149.00" then "$298.00" then "$447.00"; the pen reads "$349.00", "$698.00", "$1,047.00"; Wegovy HD reads "$399.00", "$798.00", "$1,197.00". Not one of them carries a bulk rate.

That is worth saying because nearly every telehealth seller on this site prices a longer commitment lower, and a reader who has learned to expect that will assume the same here. Prepaying NovoCare buys fewer trips through the pharmacy, not a discount, which is why our table above shows the monthly figure and nothing else.

It also sells Ozempic, and we leave it out

The same cash programme covers Ozempic, and its prices are absent from our table on purpose. Novo's own condition is that a patient must have been prescribed the medicine "for an FDA-approved indication within that product's labeling" — and Ozempic is labelled for type 2 diabetes, not weight management. Putting its price beside Wegovy's would place a diabetes medicine in a weight-loss comparison, which is a use its label does not carry.